Great announcement. In summary 1102 is shaping up to be a wonder drug for inflammation and fibrosis. Expect another round of SP upgrades from brokers. Wilson's current 12 month target 63 cents. Morgan's, 43 cents, both valuations will be upgraded when derisked with EMA trial approval.. Exciting times ahead...Big Pharma to step in soon...
Ann: New data supports ATL1102s broader clinical potential, page-21
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $26.62K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 113467 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 98248 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |